Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS
· Delayed Price · Currency is USD
0.550
-0.020 (-3.51%)
Dec 20, 2024, 4:00 PM EST
Elite Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 71.17 | 56.63 | 34.16 | 32.26 | 25.38 | 17.99 | Upgrade
|
| Revenue Growth (YoY) | 73.45% | 65.79% | 5.87% | 27.11% | 41.05% | 137.76% | Upgrade
|
| Cost of Revenue | 39.34 | 30.27 | 17.56 | 17.47 | 13.51 | 10.02 | Upgrade
|
| Gross Profit | 31.83 | 26.36 | 16.59 | 14.8 | 11.87 | 7.98 | Upgrade
|
| Selling, General & Admin | 8.19 | 7.15 | 5.12 | 4.46 | 3.32 | 3.35 | Upgrade
|
| Research & Development | 7.25 | 6.88 | 6.2 | 4.05 | 5.11 | 5.53 | Upgrade
|
| Operating Expenses | 17.22 | 15.57 | 12.63 | 9.72 | 9.76 | 10.26 | Upgrade
|
| Operating Income | 14.61 | 10.79 | 3.97 | 5.07 | 2.1 | -2.29 | Upgrade
|
| Interest Expense | -0.84 | -0.59 | -1.11 | -0.19 | -0.26 | -0.36 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.01 | 0 | 0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -22.32 | -11.52 | 0.42 | 1.43 | 1.24 | -1.11 | Upgrade
|
| EBT Excluding Unusual Items | -8.53 | -1.3 | 3.28 | 6.3 | 3.08 | -3.74 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 1 | - | 0.05 | 1.5 | Upgrade
|
| Asset Writedown | - | - | -0.29 | - | - | - | Upgrade
|
| Other Unusual Items | 1.76 | 1.76 | - | 0.86 | 1.96 | - | Upgrade
|
| Pretax Income | -6.77 | 0.46 | 3.99 | 7.16 | 5.09 | -2.24 | Upgrade
|
| Income Tax Expense | -0.38 | -19.65 | 0.42 | -1.74 | - | 0 | Upgrade
|
| Net Income | -6.39 | 20.11 | 3.56 | 8.9 | 5.09 | -2.24 | Upgrade
|
| Net Income to Common | -6.39 | 20.11 | 3.56 | 8.9 | 5.09 | -2.24 | Upgrade
|
| Net Income Growth | - | 464.56% | -59.97% | 74.87% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 1,043 | 1,015 | 1,013 | 1,011 | 943 | 832 | Upgrade
|
| Shares Outstanding (Diluted) | 1,043 | 1,023 | 1,013 | 1,011 | 943 | 993 | Upgrade
|
| Shares Change (YoY) | 2.67% | 1.02% | 0.23% | 7.17% | -5.06% | 21.68% | Upgrade
|
| EPS (Basic) | -0.01 | 0.02 | 0.00 | 0.01 | 0.01 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.01 | 0.02 | 0.00 | 0.01 | 0.00 | -0.00 | Upgrade
|
| EPS Growth | - | 537.54% | -57.99% | 81.05% | - | - | Upgrade
|
| Free Cash Flow | 2.58 | -4.09 | -2.4 | 6.01 | 2.86 | -1.83 | Upgrade
|
| Free Cash Flow Per Share | 0.00 | -0.00 | -0.00 | 0.01 | 0.00 | -0.00 | Upgrade
|
| Gross Margin | 44.73% | 46.55% | 48.58% | 45.86% | 46.76% | 44.34% | Upgrade
|
| Operating Margin | 20.53% | 19.05% | 11.62% | 15.72% | 8.29% | -12.70% | Upgrade
|
| Profit Margin | -8.98% | 35.51% | 10.43% | 27.58% | 20.05% | -12.45% | Upgrade
|
| Free Cash Flow Margin | 3.63% | -7.23% | -7.02% | 18.63% | 11.28% | -10.16% | Upgrade
|
| EBITDA | 16.12 | 12.11 | 5.23 | 6.27 | 3.4 | -0.98 | Upgrade
|
| EBITDA Margin | 22.65% | 21.39% | 15.32% | 19.42% | 13.41% | -5.44% | Upgrade
|
| D&A For EBITDA | 1.51 | 1.32 | 1.26 | 1.19 | 1.3 | 1.31 | Upgrade
|
| EBIT | 14.61 | 10.79 | 3.97 | 5.07 | 2.1 | -2.29 | Upgrade
|
| EBIT Margin | 20.53% | 19.05% | 11.62% | 15.72% | 8.29% | -12.70% | Upgrade
|
| Effective Tax Rate | - | - | 10.64% | - | - | - | Upgrade
|
| Revenue as Reported | 71.17 | 56.63 | 34.16 | 32.26 | 25.38 | 17.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.